



Your PepMix™ for

- > Immune Monitoring,
- > Epitope Discovery and
- > Adoptive Immunotherapy

PepMixes™ are antigen-spanning peptide pools and mixed epitope pools for T-cell assays and other immunological applications.

jpt

Innovative Peptide Solutions

Together with its worldwide partners JPT Peptide Technologies developed a robust and validated approach to generate defined peptide pools in a highly acknowledged quality according to DIN EN ISO 9001:2000 standards. PepMix™ is a set of chemically synthesized overlapping peptides representing entire antigens.

Your Applications

- Vaccine efficacy testing
- Measurement of antigen specific T-cell responses
- T-lymphocyte epitope discovery
- Correlation of antigen-specific T-cell responses with immune status
- Generation of antigen specific T-lymphocytes for adoptive immunotherapy

Your PepMix™ Benefits

- Simultaneous detection of CD4 and CD8 responses in a single sample (CEF pools: CD8 only)
- Equivalent or better stimulation of T-cell responses compared to whole protein antigens
- Easier detection of T-cell responses in stored blood and PBM cells compared to whole protein antigens
- Extended shelf life and superior batch-to-batch reproducibility compared to whole protein antigens

You may apply PepMixes™ with

all standard T-cell assays such as **ELISPOT, CTL, intracellular Cytokine assays**

Ready-to-use PepMixes™

JPT offers a constantly growing variety of available PepMixes™ relevant for:

infectious diseases

- CEF pool (standard)
- CEF pool (extended)
- pp65 (HCMVA)
- IE-1 (HCMVA)
- IE-2 (HCMVA) **NEW**
- BKV (capsid protein VP1)
- BKV (capsid protein VP2) **NEW**
- BKV (VP3) **NEW**
- BKV (large T antigen)
- BKV (small T antigen) **NEW**
- EBV (LMP1)
- EBV (LMP2)
- HCV (NS3)
- HAAdV-3 (hexon protein)
- HIV (gag cons. motif)
- Influenza A (MP1 protein) **NEW**
- Influenza A (NP protein) **NEW**

cancer

- NY-ESO-1 (CTG1B_human)
- Prame/OIP4 (MAPE_human)
- WT1 (WT33)
- Melan-A/MART-1 **NEW**
(MAR-1 human)
- TARP **NEW**





Coming soon

additional pools including:

- > HAAdV-5 (penton protein)
- > UL40 (HCMVA)
- > BZLF1 (EBV)
- > MAGE4 (MAGA4_HUMAN)

Individual PepMix™ Services & Custom Peptides

For specific PepMixes™ chose custom designed peptide pools (e.g. for autoimmune diseases) and individual epitope synthesis provided by JPT's custom synthesis program:

-  globally respected quality level
-  highest batch-to-batch reproducibility
-  DIN EN ISO 9001:2000 quality management standards
-  reputable references in academia and pharmaceutical industry

References

Functional comparison of T-cells recognizing Cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients, Lacey et al., J. Infect. Dis. 194 (10) (2006), p. 1410–1421.

Acquisition of direct antiviral effector functions by CMV-specific CD4+ T-lymphocytes with cellular maturation, Casazza et al., J. Exp. Med. 203 (13) (2006), p. 2865–2877.

Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T-cells, Bunde et al., Eur. J. Exp. Med. 201 (7) (2005), p. 1031-1036.

HLA type-independent generation of antigen-specific T-cells for adoptive immunotherapy, Hammer et al., Eur. J. Immunol. Vol. 35 (2005), p. 2250-2258.

A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays, Currier et al., Journal of Immunological Methods. 260 (2002) p. 157-172.

Testimonials

"The focus of the Clinical Immunology Group at the German Rheumatism Research Centre is to study the role of cells and molecules in the origin and progression of autoimmune and other diseases. In our hands PepMixes™ were found to be effective in monitoring the immune status of various patient populations but show also promise for the development of novel immuno therapy approaches."

Andreas Thiel PhD.

(German Rheumatism Research Centre, Clinical Immunology, Berlin, Germany)

"I have used JPT's peptide pools (PepMix™) for years now, with great satisfaction! First CMV derived peptides and now also EBV. So far we have published data in one publication and plan several more in the near future."

Anna Karin Lidehäll

(Uppsala University, Clinical Immunology, Uppsala, Sweden)





Find your JPT product at one glance

Immuno Tools

PepSpot™ Array Service
PepMix™
RepliTope™
Customized Antibodies

Peptides & Arrays

PepStar™ Microarrays
Custom Peptides
Macroscale Peptide Sets
Microscale Peptide Sets
BioTides™

Enzyme Profiling Tools

Kinase Profiling Tools
Phosphatase Profiling Tools
Protease Profiling Tools



Innovative Peptide Solutions

JPT Peptide Technologies

www.jpt.com | peptide@jpt.com

European Head Office

T +49-30-6392-7878

F +49-30-6392-7888

USA/Canada

T 1-888-578-2660

F 1-888-578-2666